Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

55 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Pattern of recurrence and overall survival in esophagogastric cancer after perioperative FLOT and clinical outcomes in MSI-H population: the PROSECCO Study.
Nappo F, Fornaro L, Pompella L, Catanese S, Lavacchi D, Spallanzani A, Cappetta A, Puzzoni M, Murgioni S, Barsotti G, Tirino G, Pellino A, Vivaldi C, Strippoli A, Aprile G, Di Donato S, Mazza E, Prisciandaro M, Antonuzzo L, Zagonel V, Cascinu S, De Vita F, Lonardi S. Nappo F, et al. Among authors: puzzoni m. J Cancer Res Clin Oncol. 2023 Aug;149(9):6601-6611. doi: 10.1007/s00432-023-04636-y. Epub 2023 Feb 16. J Cancer Res Clin Oncol. 2023. PMID: 36795195 Free PMC article.
The role of primary tumour sidedness, EGFR gene copy number and EGFR promoter methylation in RAS/BRAF wild-type colorectal cancer patients receiving irinotecan/cetuximab.
Demurtas L, Puzzoni M, Giampieri R, Ziranu P, Pusceddu V, Mandolesi A, Cremolini C, Masi G, Gelsomino F, Antoniotti C, Loretelli C, Meriggi F, Zaniboni A, Falcone A, Cascinu S, Scartozzi M. Demurtas L, et al. Among authors: puzzoni m. Br J Cancer. 2017 Jul 25;117(3):315-321. doi: 10.1038/bjc.2017.178. Epub 2017 Jun 20. Br J Cancer. 2017. PMID: 28632725 Free PMC article.
First-line FOLFIRI and bevacizumab in patients with advanced colorectal cancer prospectively stratified according to serum LDH: final results of the GISCAD (Italian Group for the Study of Digestive Tract Cancers) CENTRAL (ColorEctalavastiNTRiAlLdh) trial.
Giampieri R, Puzzoni M, Daniele B, Ferrari D, Lonardi S, Zaniboni A, Cavanna L, Rosati G, Pella N, Zampino MG, Sozzi P, Germano D, Zagonel V, Codecà C, Libertini M, Labianca R, Cascinu S; Italian Group for the Study of Gastrointestinal Cancer (GISCAD); Scartozzi M. Giampieri R, et al. Among authors: puzzoni m. Br J Cancer. 2017 Oct 10;117(8):1099-1104. doi: 10.1038/bjc.2017.234. Epub 2017 Sep 19. Br J Cancer. 2017. PMID: 28926529 Free PMC article. Clinical Trial.
Prognostic Value of Thyroid Hormone Ratios in Patients With Advanced Metastatic Colorectal Cancer Treated With Regorafenib: The TOREADOR Study.
Schirripa M, Pasqualetti G, Giampieri R, Scartozzi M, Lonardi S, Rumanò L, Bergamo F, Stragliotto S, Murgioni S, Alberti G, Rizzato MD, Prete AA, Puzzoni M, Pusceddu V, Ziranu P, Pani F, Mariotti S, Zagonel V, Monzani F, Loupakis F. Schirripa M, et al. Among authors: puzzoni m. Clin Colorectal Cancer. 2018 Sep;17(3):e601-e615. doi: 10.1016/j.clcc.2018.05.013. Epub 2018 Jun 8. Clin Colorectal Cancer. 2018. PMID: 30149875
Angiogenesis Genotyping and Clinical Outcomes in Patients with Advanced Hepatocellular Carcinoma Receiving Sorafenib: The ALICE-2 Study.
Faloppi L, Puzzoni M, Casadei Gardini A, Silvestris N, Masi G, Marisi G, Vivaldi C, Gadaleta CD, Ziranu P, Bianconi M, Loretelli C, Demurtas L, Lai E, Giampieri R, Galizia E, Ulivi P, Battelli N, Falcone A, Cascinu S, Scartozzi M. Faloppi L, et al. Among authors: puzzoni m. Target Oncol. 2020 Feb;15(1):115-126. doi: 10.1007/s11523-020-00698-x. Target Oncol. 2020. PMID: 32020517
Thyroid hormones ratio is a major prognostic marker in advanced metastatic colorectal cancer: Results from the phase III randomised CORRECT trial.
Pasqualetti G, Schirripa M, Dochy E, Fassan M, Ziranu P, Puzzoni M, Scartozzi M, Alberti G, Lonardi S, Zagonel V, Monzani F, Loupakis F. Pasqualetti G, et al. Among authors: puzzoni m. Eur J Cancer. 2020 Jul;133:66-73. doi: 10.1016/j.ejca.2020.04.023. Epub 2020 May 20. Eur J Cancer. 2020. PMID: 32446145 Clinical Trial.
From CENTRAL to SENTRAL (SErum aNgiogenesis cenTRAL): Circulating Predictive Biomarkers to Anti-VEGFR Therapy.
Giampieri R, Ziranu P, Daniele B, Zizzi A, Ferrari D, Lonardi S, Zaniboni A, Cavanna L, Rosati G, Casagrande M, Pella N, Demurtas L, Zampino MG, Sozzi P, Pusceddu V, Germano D, Lai E, Zagonel V, Codecà C, Libertini M, Puzzoni M, Labianca R, Cascinu S, Scartozzi M. Giampieri R, et al. Among authors: puzzoni m. Cancers (Basel). 2020 May 22;12(5):1330. doi: 10.3390/cancers12051330. Cancers (Basel). 2020. PMID: 32456056 Free PMC article.
Anti-EGFR Therapy in Metastatic Small Bowel Adenocarcinoma: Myth or Reality?
Dell'Aquila E, Zeppola T, Stellato M, Pantano F, Scartozzi M, Madaudo C, Pietrantonio F, Cremolini C, Aprile G, Vincenzi B, Moretto R, Puzzoni M, Garattini SK, Lobefaro R, Tonini G, Santini D. Dell'Aquila E, et al. Among authors: puzzoni m. Clin Med Insights Oncol. 2020 Aug 4;14:1179554920946693. doi: 10.1177/1179554920946693. eCollection 2020. Clin Med Insights Oncol. 2020. PMID: 32821190 Free PMC article.
Correction to: Angiogenesis Genotyping and Clinical Outcomes in Patients with Advanced Hepatocellular Carcinoma Receiving Sorafenib: The ALICE‑2 Study.
Faloppi L, Puzzoni M, Gardini AC, Silvestris N, Masi G, Marisi G, Vivaldi C, Gadaleta CD, Ziranu P, Bianconi M, Loretelli C, Demurtas L, Lai E, Giampieri R, Galizia E, Ulivi P, Battelli N, Falcone A, Cascinu S, Scartozzi M. Faloppi L, et al. Among authors: puzzoni m. Target Oncol. 2020 Dec;15(6):801-802. doi: 10.1007/s11523-020-00773-3. Target Oncol. 2020. PMID: 33170485
55 results